All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
5 warning events since 2017; the latest 2024-07-18.
From the record
Bionano Genomics, Inc.'s filings since 2017 show 5 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2024-07-18); an auditor change (8-K item 4.01, the latest 2020-05-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+13.2% a year over 8 filed years; profitable in 0 of 8.
From the record
Bionano Genomics, Inc.'s 8 filed years say what it did: revenue went from $12 million in fiscal 2018 to $29 million in fiscal 2025, up 13.2% a year; it rose in 3 of 7 years; the deepest fall was 29% from fiscal 2018 to fiscal 2020; net income was positive in 0 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Bionano Genomics, Inc.'s shareholder treatment is put at 0.7 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 7% of 21 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -59%: lost 59¢ per shareholder dollar. Leverage 40%: owes 40¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Bionano Genomics, Inc. lost about 59 cents for every dollar of shareholders' money, and gross profitability: its products earned about 18 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 40 cents per dollar of assets, and net share issuance: its share count grew 328.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 30% of 21 in its family; net margin -92.6%.
From the record
Bionano Genomics, Inc.'s standing among 21 graded names in its industry family: revenue of $29 million in fiscal 2025 ranks in the bottom 17% by size; a net margin of -92.6% ranks in the bottom 31%; revenue growth of 0.8% a year over the last 3 filed years ranks in the bottom 43% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 49% of 21 in its family for leadership; chief executive since 2026.
From the record
Bionano Genomics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Luderer, Albert (Interim Chief Executive, as filed), filing under that title since 2026-08-21, 3 months (bottom 3% of its family); the 12 officers and directors filing in the last fifteen months have been on the record a median of 7 years (top 26%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 12 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 21 in its family for room to expand.
From the record
Bionano Genomics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $3 million against no long-term debt tagged leaves 4.1% of its assets as net cash, bottom 43% of its family; cash from operations less capital spending is -57.3% of revenue (bottom 40%); a gross margin of 46.3% (bottom 31%); research spending of 39.9% of revenue (top 27%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 17% of 21 in its family for growth drivers.
From the record
Bionano Genomics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 0.8% a year over the last three filed years against 13.2% over all 8, slowing (bottom 33% of its family); the newest year grew -7.4% (bottom 17%); research spending grew -38.6% a year (bottom 3%) (its annual reports). Bionano Genomics, Inc. reported 4 product lines in fiscal 2025: Consumable Revenue at $14 million (49%), Software Revenue at $6 million (23%), Instrument Revenue at $6 million (22%), and 1 more; 2 of 4 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 36% of 20 in its family for expectations against reality.
From the record
Bionano Genomics, Inc.'s newest year against its own record: revenue of $29 million in fiscal 2025 came in 12% below the $32 million its prior three years' pace pointed to (bottom 13% of its family); net income of $26 million against a prior three-year average of $159 million (top 12%); a net margin of -92.6% against losses larger than its revenue before (top 7%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made